Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman′s disease in HIV infection: a clinical and pathological study of 20 patients[J]. AIDS,1996,10:61-67.
[3]
Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease[J]. Korean J Hematol,2012,47:163-177.
[4]
Kurokawa T, Suzuki S, Kawaguchi K, et al. Castleman disease presenting with ophthalmic signs and symptoms[J]. Am J Ophthalmol,1999,128:114-116.
[5]
Ibrahim K, Maghfoor I, Elghazaly A, et al. Successful treatment of steroid-refractory autoimmune thrombocytopenia associatedwith Castleman disease with anti-CD-20 antibody (rituximab) [J]. Hematol Oncol Stem Cell Ther,2011,4:100-102.
[6]
Hoffmann C, Schmid H, Muller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric[J]. Castleman disease. Blood,2011,118:3499-3503.
[7]
Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric. Castleman disease[J]. Blood,2010,116:3627-3634.
[8]
Galeotti C, Boucheron A, Guillaume S, et al. Sustained remission of multicentric Castleman disease in children treated withtocilizumab, an anti-interleukin-6 receptor antibody[J]. Mol Cancer Ther,2012,11:1623-1626.